Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.64
CTIX's Cash to Debt is ranked lower than
71% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CTIX: 2.64 )
Ranked among companies with meaningful Cash to Debt only.
CTIX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 3.51 Max: No Debt
Current: 2.64
F-Score: 3
Z-Score: 4.08
WACC vs ROIC
14.85%
-4043.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -212.24
CTIX's ROE (%) is ranked lower than
93% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CTIX: -212.24 )
Ranked among companies with meaningful ROE (%) only.
CTIX' s ROE (%) Range Over the Past 10 Years
Min: -319.44  Med: -235.00 Max: -161.9
Current: -212.24
-319.44
-161.9
ROA (%) -93.33
CTIX's ROA (%) is ranked lower than
87% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CTIX: -93.33 )
Ranked among companies with meaningful ROA (%) only.
CTIX' s ROA (%) Range Over the Past 10 Years
Min: -2870.38  Med: -215.36 Max: -104.45
Current: -93.33
-2870.38
-104.45
ROC (Joel Greenblatt) (%) -26277.31
CTIX's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CTIX: -26277.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -41215.38  Med: -37416.78 Max: -33618.18
Current: -26277.31
-41215.38
-33618.18
EBITDA Growth (3Y)(%) 28.80
CTIX's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CTIX: 28.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.7  Med: 47.20 Max: 94.9
Current: 28.8
-5.7
94.9
EPS Growth (3Y)(%) 27.50
CTIX's EPS Growth (3Y)(%) is ranked higher than
82% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CTIX: 27.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.9  Med: 50.90 Max: 94.9
Current: 27.5
-0.9
94.9
» CTIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CTIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:PETX, NAS:CMRX, XKRX:041910, ROCO:1760, XKRX:011000, NAS:CRIS » details
Cellceutix Corp is a biopharmaceutical company. The Company is engaged in the business of developing small molecule therapies to treat diseases in the areas of cancer and inflammatory disease.

Cellceutix Corporation, formerly known as EconoShare was incorporated on August 1, 2005 in the State of Nevada and was organized for the purpose of developing a B2B website for an Asset Sharing market place and transaction system. On December 6, 2007, EconoShare, Inc. acquired Cellceutix Pharma, Inc., a privately owned Delaware corporation with Cellceutix Pharma becoming a wholly-owned subsidiary of EconoShare, Inc. As a result of the Exchange with Cellceutix Pharma, Inc., the Company has adopted the business plan of Cellceutix Pharma, Inc. and now is into an early stage developmental biopharmaceutical Company. It has acquired rights to seven (7) different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or might exist in the future. The Company would initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin(tm), for the treatment of certain cancers. This compound is furthest along in in-vivo studies in small animals. Based on the results, the Company has decided to advance Kevetrin along the regulatory and clinical pathway. The Company's current portfolio of product candidates in pre-clinical development includes: (i) two (2) anti-cancer agents targeting multiple tumors; (ii) one (1) candidate targeting psoriasis; (iii) one (1) candidate targeting rheumatoid arthritis; (iv) one (1) candidate with potential for indications of osteo-arthritis/asthma; (v) one (1) candidate with a potential for indications of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson's Disease; and (vi) a small molecule with potential for development to treat hypertensive emergency. Its product candidate, Kevetrin. Kevetrin is initially being developed to treat certain cancers. The Company is in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of cancer and inflammatory disease. The Company's compounds are still in preclinical development. It competes with biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to its operations. In the United States, drugs are subject to rigorous regulation by the United States Food and Drug Administration ('FDA'). The Federal Food, Drug and Cosmetic Act, and other federal and state statutes and regulations, govern the testing, manufacture, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of its products.

Ratios

vs
industry
vs
history
P/B 63.73
CTIX's P/B is ranked lower than
98% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CTIX: 63.73 )
Ranked among companies with meaningful P/B only.
CTIX' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 338.2
Current: 63.73
0
338.2
Current Ratio 0.69
CTIX's Current Ratio is ranked lower than
92% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CTIX: 0.69 )
Ranked among companies with meaningful Current Ratio only.
CTIX' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.18 Max: 2.4
Current: 0.69
0.01
2.4
Quick Ratio 0.69
CTIX's Quick Ratio is ranked lower than
90% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CTIX: 0.69 )
Ranked among companies with meaningful Quick Ratio only.
CTIX' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.18 Max: 2.4
Current: 0.69
0.01
2.4

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -6.79
CTIX's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CTIX: -6.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10.45  Med: 0.00 Max: 0
Current: -6.79
-10.45
0

More Statistics

EPS (TTM) $ -0.11
Beta1.74
Short Percentage of Float0.00%
52-Week Range $0.94 - 3.65
Shares Outstanding (Mil)122.54
» More Articles for CTIX

Headlines

Articles On GuruFocus.com
Interview with CEO of Cellceutix Corporation: Leo Ehrlich Nov 15 2011 

More From Other Websites
Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis May 26 2016
Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint May 24 2016
CELLCEUTIX CORP Financials May 17 2016
Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to... May 11 2016
CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report May 09 2016
Cellceutix Institutes "Database Soft Lock" on Its Phase 2 Psoriasis Clinical Trial, Top Line Results... Apr 19 2016
CELLCEUTIX CORP Files SEC form 8-K, Regulation FD Disclosure Apr 08 2016
Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for... Mar 31 2016
CELLCEUTIX CORP Files SEC form 8-K, Other Events Mar 31 2016
Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis Mar 30 2016
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With... Mar 17 2016
Technical Insights on Equity Movements -- Research Reports on ALUF Holdings, Vantage Drilling,... Mar 09 2016
Cellceutix Corporation Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board Mar 08 2016
Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Top-Line Data... Mar 01 2016
Cellceutix Submits Special Protocol Assessment Request to FDA for Phase 3 Clinical Trial of... Feb 26 2016
Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21... Feb 22 2016
Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors Feb 16 2016
Cellceutix Files Motion to Dismiss Complaint Filed by The Rosen Law Firm Feb 12 2016
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer Feb 10 2016
Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of... Feb 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)